Improving Detection and Outcomes in Patients With Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAPI PET Imaging (NCT07285993)
Eligible patients:
Women age ≥ 18 years with confirmed presence of metastatic/advanced invasive lobular breast cancer. Additional eligibility criteria can be found here.
Description of Trial/Summary:
This pilot imaging study compares a novel PET scan (FAPI PET/CT) with the current standard (FDG PET/CT) in patients with metastatic invasive lobular breast cancer. Participants will undergo both scans within a short time period, allowing researchers to directly evaluate differences in lesion detection, tumor visibility, and clinical usefulness, including whether the new imaging approach may better inform treatment decisions.
Why is this study beneficial?/Important?
Invasive lobular breast cancer is often difficult to detect with standard imaging, which can lead to underestimation of disease burden. This study evaluates a novel imaging approach that may better identify metastatic lesions and provide a more accurate picture of disease extent. Improved detection could help guide treatment decisions and ultimately improve care for people living with metastatic ILC.
Principal Investigator:
Randy Yeh, MD
More information/Trial Contact:
Ilda Bander
Phone: (212) 241-0763
Email: Ilda.Bander@mountsinai.org
Rashmi Unawane
Phone: (212) 824-2385
Email: rashmi.unawane@mssm.edu
Trial Location:
Icahn School of Medicine at Mount Sinai, New York, New York, USA
For more information:
https://clinicaltrials.gov/study/NCT07285993#study-overview